"The ginkgo extract used in this study is different from the high-quality ginkgo extracts used in published clinical trials showing safety and various beneficial activities of ginkgo," said Mark Blumenthal , founder and executive director of ABC. "That is, the Shanghai ginkgo extract used by NTP does not represent the quality of German ginkgo extract that is the world standard for ginkgo. It is highly unfortunate that NTP chose to use this ginkgo extract as it means that the results of the NTP's studies are not applicable to the standard-setting ginkgo extracts."
In addition, ABC noted that the dosage levels administered to the test animals was significantly higher (up to 55-108 times higher) than the levels of ginkgo extract that are normally ingested by consumers (120-240 milligrams per day), as calculated by ABC's consulting toxicologist.
"At best, what NTP can say is that significantly high doses of this particular Shanghai Chinese ginkgo extract – when added to a corn-oil base – produced cancer in the lab animals," added Blumenthal.
ABC emphasized that the NTP studies are not intended to imply the potential adverse effect in humans.
"The NTP's public message, and the resulting media reports, totally miss this point about the actual identity of the ginkgo extract and the high-dosage levels, and will probably cause confusion among consumers and health professionals alike," added Blumenthal.
"Almost anything will create cancer in rats and mice when it's fed to them at high doses for two years," said Bill J. Gurley , PhD, professor of pharmaceutical sciences in the College of Pharmacy at the University of Arkansas School for Medical Sciences, Little Rock. "All toxicologists and pharmacologists are aware of the susceptibility of certain strains of rodents used fo
|SOURCE American Botanical Council|
Copyright©2012 PR Newswire.
All rights reserved